E. Papadakis

1.8k total citations
40 papers, 1.4k citations indexed

About

E. Papadakis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, E. Papadakis has authored 40 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in E. Papadakis's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (17 papers) and Cancer Treatment and Pharmacology (11 papers). E. Papadakis is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Research Studies (17 papers) and Cancer Treatment and Pharmacology (11 papers). E. Papadakis collaborates with scholars based in Greece, United States and Kuwait. E. Papadakis's co-authors include Vassilis Georgoulias, Ph. Palamidas, Xanthi Tsiafaki, M. Veslemes, Demetrios�� Spandidos, A. Alexopoulos, A. Rapti, Ioannis G. Vlachonikolis, Nikolaos Soulitzis and N. Androulakis and has published in prestigious journals such as The Lancet, Circulation and Journal of Clinical Oncology.

In The Last Decade

E. Papadakis

36 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Papadakis Greece	18	1.1k	756	544	299	131	40	1.4k
Hideya Takeuchi Japan	17	584 0.5×	358 0.5×	371 0.7×	95 0.3×	46 0.4×	70	1.3k
J.J. Lafitte France	13	504 0.5×	481 0.6×	296 0.5×	126 0.4×	46 0.4×	39	930
Reury-Perng Perng Taiwan	20	598 0.6×	748 1.0×	164 0.3×	143 0.5×	27 0.2×	51	1.1k
Carmen Nuzzo Italy	14	481 0.4×	312 0.4×	403 0.7×	70 0.2×	56 0.4×	31	1.0k
Toshifumi Matsumoto Japan	23	892 0.8×	533 0.7×	199 0.4×	234 0.8×	115 0.9×	75	1.7k
Luis Paz‐Ares Spain	13	784 0.7×	675 0.9×	357 0.7×	153 0.5×	95 0.7×	27	1.6k
Raquel Catarino Portugal	21	584 0.5×	200 0.3×	474 0.9×	238 0.8×	99 0.8×	68	1.2k
H. J. Illiger Germany	11	555 0.5×	266 0.4×	386 0.7×	74 0.2×	35 0.3×	28	974
Satya Das United States	16	1.3k 1.2×	292 0.4×	213 0.4×	489 1.6×	35 0.3×	54	1.6k
Soon‐Beom Kang South Korea	24	354 0.3×	188 0.2×	277 0.5×	287 1.0×	91 0.7×	64	1.5k

Countries citing papers authored by E. Papadakis

Since Specialization

Citations

This map shows the geographic impact of E. Papadakis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Papadakis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Papadakis more than expected).

Fields of papers citing papers by E. Papadakis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Papadakis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Papadakis. The network helps show where E. Papadakis may publish in the future.

Co-authorship network of co-authors of E. Papadakis

This figure shows the co-authorship network connecting the top 25 collaborators of E. Papadakis. A scholar is included among the top collaborators of E. Papadakis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Papadakis. E. Papadakis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sotiropoulos, Damianos, Vasileios Papadopoulos, Maria Dimou, et al.. (2015). Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. Blood. 126(23). 5192–5192.

Galanakis, Dennis K., Marguerite Neerman‐Arbez, Stephen O. Brennan, et al.. (2014). Thromboelastographic phenotypes of fibrinogen and its variants: Clinical and non-clinical implications. Thrombosis Research. 133(6). 1115–1123. 21 indexed citations

Kuperman, Amir A., Gili Kenet, E. Papadakis, & Benjamin Brenner. (2011). Intraventricular Hemorrhage in Preterm Infants: Coagulation Perspectives. Seminars in Thrombosis and Hemostasis. 37(7). 730–736. 21 indexed citations

Nikiteas, Nikolaos, E. Papadakis, George Rallis, et al.. (2008). P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population.. PubMed. 28(2A). 1039–43. 31 indexed citations

Papadakis, E., et al.. (2007). Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. International Urology and Nephrology. 38(3-4). 795–800. 20 indexed citations

Arvanitis, Demetrios A., E. Papadakis, Alexandros Zafiropoulos, & Demetrios�� Spandidos. (2003). Fractional allele loss is a valuable marker for human lung cancer detection in sputum. Lung Cancer. 40(1). 55–66. 14 indexed citations

Papadakis, E., Nikolaos Soulitzis, & Demetrios�� Spandidos. (2002). Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. British Journal of Cancer. 87(9). 1013–1018. 86 indexed citations

Agelaki, Sofia, Charalambos Kouroussis, John Souglakos, et al.. (2001). Vinorelbine-Based Regimens as Salvage Treatment in Patients with Advanced Non-Small Cell Lung Cancer: Two Parallel Multicenter Phase II Trials. Oncology. 60(3). 235–241. 5 indexed citations

Georgoulias, Vassilis, George Samonis, E. Papadakis, et al.. (2001). Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer. 34. 47–51. 29 indexed citations

10.

Mavroudis, Dimitriοs, E. Papadakis, M. Veslemes, et al.. (2001). A multicenter randomized clinical trial comparing paclitaxel–cisplatin–etoposide versus cisplatin–etoposide as first-line treatment in patients with small-cell lung cancer. Annals of Oncology. 12(4). 463–470. 108 indexed citations

11.

Georgoulias, Vassilis, E. Papadakis, A. Alexopoulos, et al.. (2001). Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. The Lancet. 357(9267). 1478–1484. 276 indexed citations

12.

Agelaki, Sofia, Charalambos Kouroussis, John Souglakos, et al.. (2001). Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small cell lung cancer. A multicenter phase II study. Lung Cancer. 34. 77–80. 12 indexed citations

13.

Mavroudis, Dimitriοs, E. Papadakis, M. Veslemes, et al.. (1999). Paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as first line treatment in small cell lung cancer (SCLC): a preliminary analysis of a multicenter randomized phase III trial. European Journal of Cancer. 35. S247–S247. 2 indexed citations

14.

Kouroussis, Ch., N. Androulakis, S. Kakolyris, et al.. (1999). Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemotherapy and Pharmacology. 43(3). 257–262. 35 indexed citations

15.

Georgoulias, Vassilis, N. Androulakis, Meletios Α. Dimopoulos, et al.. (1998). First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. Annals of Oncology. 9(3). 331–334. 65 indexed citations

16.

Androulakis, N., Charalambos Kouroussis, S. Kakolyris, et al.. (1998). Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study. Annals of Oncology. 9(10). 1127–1130. 47 indexed citations

17.

Georgoulias, Vassilis, C. Kourousis, Stylianos Kakolyris, et al.. (1997). Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.. PubMed. 24(4 Suppl 12). S12–61. 26 indexed citations

18.

Skarlos, D., E. Samantas, P. Kosmidis, et al.. (1994). Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. Annals of Oncology. 5(7). 601–607. 195 indexed citations

19.

Kosmidis, P., N. Mylonakis, D. Skarlos, et al.. (1994). A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. Annals of Oncology. 5(2). 159–162. 25 indexed citations

20.

Linardopoulos, Spiros, et al.. (1993). Human lung and bladder carcinoma tumors as compared to their adjacent normal tissue have elevated AP-1 activity associated with the retinoblastoma gene promoter.. PubMed. 13(1). 257–62. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact